This early-stage study is testing the safety and initial effects of an experimental drug called OMO-103 when given alongside standard chemotherapy (gemcitabine/nab-paclitaxel) to patients with newly diagnosed metastatic pancreatic cancer. The main goal is to find a safe dose and …
Phase: PHASE1 • Sponsor: Peptomyc S.L. • Aim: Disease control
Last updated Mar 30, 2026 14:29 UTC